Alecensa is a cancer medicine used to treat a type of lung cancer called non-small-cell lung cancer (NSCLC). It is only used when the cancer is ‘ALK-positive’, which means that cancer cells have changes in the gene that makes a protein called anaplastic lymphoma kinase (ALK). Alecensa is used on its own in adults with: - advanced NSCLC that has never been treated before or has already been treated with a cancer medicine called Xalkori (crizotinib); - NSCLC that has been removed by surgery (adjuvant treatment) and is at high risk of coming back. Alecensa contains the active substance alectinib.
Therapeutic Indication
### Therapeutic indication Adjuvant treatment of resected non small cell lung cancer (NSCLC) Alecensa as monotherapy is indicated as adjuvant treatment following complete tumour resection for adult patients with ALK positive NSCLC at high risk of recurrence (see section 5.1 for selection criteria). Treatment of advanced NSCLC Alecensa as monotherapy is indicated for the first line treatment of adult patients with ALK positive advanced NSCLC. Alecensa as monotherapy is indicated for the treatment of adult patients with ALK positive advanced NSCLC previously treated with crizotinib.
Therapeutic Area (MeSH)
N/AATC Code
L01ED03
ATC Item
alectinib
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| alectinib hydrochloride | N/A | 阿来替尼 |
EMA Name
Alecensa
Medicine Name
Alecensa
Aliases
N/ANo risk management plan link.
